Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera

Clinical Immunology

Volumn 122, Issue 3, 2007, Pages 279-287

  Xiong, Zeyu ^a   Yan, Yan ^a   Liu, Enli ^b   Silver, Richard T ^c   Verstovsek, Srdan ^d   Yang, Fan ^a   Wang, Hong ^a   Prchal, Josef ^e   Yang, Xiao Feng ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

IgG antibody reactions; Myeloproliferative diseases; Polycythemia vera; SEREX; Tumor antigens

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; COMPLEMENTARY DNA; HYDROXYUREA; IMATINIB; IMMUNOGLOBULIN G ANTIBODY; INITIATION FACTOR 2ALPHA; PROTAMINE P2; THALIDOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA LIBRARY; HUMAN; HUMORAL IMMUNITY; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; EUKARYOTIC INITIATION FACTOR-2; HELA CELLS; HUMANS; INTERFERON-ALPHA; JURKAT CELLS; K562 CELLS; MALE; POLYCYTHEMIA VERA; PROTAMINES; TESTIS; U937 CELLS;

EID: 33846807560     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.10.006     Document Type: Article

References (56)

1. Gilbert H.S. Current management in polycythemia vera. Semin. Hematol. 38 (2001) 25-28
2. Liu E., Jelinek J., Pastore Y.D., Guan Y., Prchal J.F., and Prchal J.T. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 101 (2003) 3294-3301
3. Lengfelder E., Berger U., and Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann. Hematol. 79 (2000) 103-109
4. Fujii S. Role of interferon-alpha and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia. Leuk. Lymphoma 38 (2000) 21-38
5. Sacchi S., Kantarjian H., O'Brien S., Cohen P.R., Pierce S., and Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J. Clin. Oncol. 13 (1995) 2401-2407
6. Xiong Z., Liu E., Yan Y., Silver R.T., Yang F., Chen I.H., Chen Y., Verstovsek S., Wang H., Prchal J., and Yang X.F. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J. Immunol. 177 (2006) 4907-4916
7. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., and Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad Sci. U. S. A. 92 (1995) 11810-11813
8. Yang X.F., Wu C.J., McLaughlin S., Chillemi A., Wang K.S., Canning C., Alyea E.P., Kantoff P., Soiffer R.J., Dranoff G., and Ritz J. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc. Natl. Acad Sci. U. S. A. 98 (2001) 7492-7497
9. Yang X.F., Wu C.J., Chen L., Alyea E.P., Canning C., Kantoff P., Soiffer R.J., Dranoff G., and Ritz J. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 62 (2002) 5517-5522
10. Wu C.J., Biernacki M., Kutok J.L., Rogers S., Chen L., Yang X.F., Soiffer R.J., and Ritz J. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin. Cancer Res. 11 (2005) 4504-4511
11. Yan Y., Phan L., Yang F., Talpaz M., Yang Y., Xiong Z., Ng B., Timchenko N.A., Wu C.J., Ritz J., Wang H., and Yang X.F. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J. Immunol. 172 (2004) 651-660
12. Ng B., Yang F., Huston D.P., Yan Y., Yang Y., Xiong Z., Peterson L.E., Wang H., and Yang X.F. Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J. Allergy Clin. Immunol. 114 (2004) 1463-1470
13. Yang F., Chen I.H., Xiong Z., Yan Y., Wang H., and Yang X.-F. Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens. Clinical Immunology 121 (2006) 121-133
14. Xiong Z., Shaibani A., Li Y.P., Yan Y., Zhang S., Yang Y., Yang F., Wang H., and Yang X.F. Alternative splicing factor ASF/SF2 is down regulated in inflamed muscle. J. Clin. Pathol. 59 (2006) 855-861
15. Y. Yan, Chen, Y, Yang, F, Chen, IH, Xiong, Z, Wang, J, Lachman, LB, Wang, H, Yang, X-F., HLA-A2.1-restricted T cells are reacted to SEREX-defined tumor antigen CML66L and suppressed by CD4+CD25+ regulatory T cells, Intl J Immunopathol and Pharmacol (in press) (Sept. 29).
16. Yang X.-F., Yan Y., Phan L., Xiong Z., and Jelinek J. Upregulation of cancer-testis antigens in polycythemia vera cells suggests their potential role in immune responses against myeloproliferation. Blood 100 (2002) 348b
17. Y. Chen, SEREX review, Cancer Immunity http://www.cancerimmunity.org/SEREX/(2004).
18. X. Yang, Mirkovic, D, Zhang, S, Zhang, QE, Yan, Y, Xiong, Z, Yang, F, Chen, IH, Li, L, Wang, H., Processing sites are different in the generation of HLA-A2.1-restricted T cell reactive tumor antigen epitopes and viral epitopes., International Journal of Immunopathology and Pharmacology 19(4), (in press).
19. Gure A.O., Tureci O., Sahin U., Tsang S., Scanlan M.J., Jager E., Knuth A., Pfreundschuh M., Old L.J., and Chen Y.T. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer 72 (1997) 965-971
20. Streilein J.W. Unraveling immune privilege. Science 270 (1995) 1158-1159
21. Chen Y.T., and Old L.J. Cancer-testis antigens: targets for cancer immunotherapy. Cancer J. Sci. Am. 5 (1999) 16-17
22. Yang F., and Yang X.F. New concepts in tumor antigens: their significance in future immunotherapies for tumors. Cell Mol. Immunol. 2 (2005) 331-341
23. Wu C.J., Yang X.F., McLaughlin S., Neuberg D., Canning C., Stein B., Alyea E.P., Soiffer R.J., Dranoff G., and Ritz J. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J. Clin. Invest. 106 (2000) 705-714
24. Yang X.F., Weber G.F., and Cantor H. A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells. Immunity 7 (1997) 629-639
25. Ng B., Yang F., Huston D.P., Yan Y., Yang Y., Xiong Z., Peterson L.E., Wang H., and Yang X.-F. Increased non-canonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J. Allergy Clin. Immunol. 114 (2004) 1463-1470
26. Zhang J., Shridhar R., Dai Q., Song J., Barlow S.C., Yin L., Sloane B.F., Miller F.R., Meschonat C., Li B.D., Abreo F., and Keppler D. Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res. 64 (2004) 6957-6964
27. B. Rosner, Multisample Inference Fifth edn. Australia, Canada, Mexico, Singapore, Spain, United Kingdom, United States: Duxbury; 2000.
28. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., Koromilas A., and Wouters B.G. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol. Cell. Biol. 22 (2002) 7405-7416
29. Raught B., Gingras A.C., James A., Medina D., Sonenberg N., and Rosen J.M. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res. 56 (1996) 4382-4386
30. Rosenwald I.B., Wang S., Savas L., Woda B., and Pullman J. Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms. Cancer 98 (2003) 1080-1088
31. Rae F.K., Hooper J.D., Nicol D.L., and Clements J.A. Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors. Mol. Carcinog. 32 (2001) 44-53
32. Utz P.J., Gensler T.J., and Anderson P. Death, autoantigen modifications, and tolerance. Arthritis Res. 2 (2000) 101-114
33. Meurs E., Chong K., Galabru J., Thomas N.S., Kerr I.M., Williams B.R., and Hovanessian A.G. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62 (1990) 379-390
34. Dimitrova D.I., Yang X., Reichenbach N.L., Karakasidis S., Sutton R.E., Henderson E.E., Rogers T.J., and Suhadolnik R.J. Lentivirus-mediated transduction of PKR into CD34(+) hematopoietic stem cells inhibits HIV-1 replication in differentiated T cell progeny. J. Interferon Cytokine Res. 25 (2005) 345-360
35. Balhorn R., Cosman M., Thornton K., Krishnan V.V., Corzett M., Bench G., Kramer C., Lee IV J., Hud N.V., Allen M., Prieto M., Meyer-Ilse W., Brown J.T., Kirz J., Zhang X., Bradbury E.M., Maki G., Braun R.E., and Breed W. Protamine mediated condensation of DNA in mammalian sperm. In: Gagnon C. (Ed). The Male Gamete: From Basic Knowledge to Clinical Applications (1999), Cache River Press, Vienna, IL 55-70
36. Yan Y., Xiong Z., Yang F., Yang Y., Ng B., Lachman L., Wang H., and Yang X.-F. Broadly immunogenic SEREX antigen CML66-L elicits humoral and cellular immune responses. FASEB J. 18 4 (2004) A58
37. Steger K., Fink L., Klonisch T., Bohle R.M., and Bergmann M. Protamine-1 and -2 mRNA in round spermatids is associated with RNA-binding proteins. Histochem. Cell Biol. 117 (2002) 227-234
38. Tefferi A., Lasho T.L., Wolanskyj A.P., and Mesa R.A. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 103 (2004) 3547-3548
39. Pahl H.L. PRV-1 mRNA expression and other molecular markers in polycythemia rubra vera. Curr. Hematol. Rep. 2 (2003) 231-236
40. Kralovics R., Stockton D.W., and Prchal J.T. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102 (2003) 3793-3796
41. Bhattachary-Chatterjee M., Nath Baral R., Chatterjee S.K., Das R., Zeytin H., Chakraborty M., and Foon K.A. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol. Immunother. 49 (2000) 133-141
42. L. Novellino, C. Castelli, G. Parmiani, A listing of human tumor antigens recognized by T cells: March 2004 update, Cancer Immunol Immunother (2004).
43. Simpson E., Scott D., and Chandler P. The male-specific histocompatibility antigen, H-Y: a history of transplantation, immune response genes, sex determination and expression cloning. Annu. Rev. Immunol. 15 (1997) 39-61
44. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
45. Patel R.C., and Sen G.C. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 17 (1998) 4379-4390
46. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., and Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad Sci. U. S. A. 100 (2003) 2610-2615
47. Matikainen S., Lehtonen A., Sareneva T., and Julkunen I. Regulation of IRF and STAT gene expression by retinoic acid. Leuk. Lymphoma 30 (1998) 63-71
48. Chelbi-alix M.K., Bobe P., Benoit G., Canova A., and Pine R. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. Oncogene 22 (2003) 9121-9130
49. Hoeppner L.H., Dubovsky J.A., Dunphy E.J., and McNeel D.G. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun. 6 (2006) 1
50. Scanlan M.J., and Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 3 (2001) 95-98
51. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee C., Gabriel S., Mercher T., D'Andrea A., Frohling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., and Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
52. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
53. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., and Zhao Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280 (2005) 22788-22792
54. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
55. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
56. Verma A., Kambhampati S., Parmar S., and Platanias L.C. Jak family of kinases in cancer. Cancer Metastasis Rev. 22 (2003) 423-434